These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3480655)

  • 1. [Diagnosis of the recurrence of epithelial ovarian cancer with the tumor marker CA 125].
    Sevelda P; Wagner G
    Wien Klin Wochenschr; 1987 Nov; 99(21):768-70. PubMed ID: 3480655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
    Crombach G; Zippel HH; Würz H
    Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experiences with the tumor markers Ca 125 and plasma ribonuclease in ovarian cancer].
    Lücke R; Benz R; Kraus H
    Geburtshilfe Frauenheilkd; 1987 Dec; 47(12):846-9. PubMed ID: 3481339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer].
    Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ["Immunosuppressive acidic protein" (IAP)--an improvement for tumor marker diagnosis in epithelial ovarian cancer?].
    Sevelda P; Haider F; Spona J
    Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):452-5. PubMed ID: 3476335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
    Sevelda P; Salzer H; Dittrich C; Spona J
    Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
    Paulick R; Kaesemann H; Caffier H
    Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of 3 markers in ovarian cancer: CA 125, CA 19,9 and CEA].
    Vigné E; Krebs B; Khater R; Mira R; Boublil JL; Jourlait A; Frenay M; Namer M
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(5):609-13. PubMed ID: 3463621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
    Crombach G; Zippel HH; Würz H
    Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
    Göcze P; Vahrson H
    Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Ca 125 as tumor marker in ovarian carcinoma.
    Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
    Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
    Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
    Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
    Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
    J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum level of the tumor marker CA 125 in ovarian pathology].
    Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
    Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Possibilities and limits of the study of tumor markers in the after-care of patients with ovarian cancer].
    Kreienberg R
    Gynakologe; 1986 Sep; 19(3):178-85. PubMed ID: 3770529
    [No Abstract]   [Full Text] [Related]  

  • 20. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
    Zaucha R; Kobierska A
    Przegl Lek; 1995; 52(2):51-3. PubMed ID: 7784616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.